A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is an open, multi-cohort phase II clinical trial, the overall design is divided into two parts: dose confirmation stage and expansion stage. Dose confirmation stage is to evaluate the safety and tolerability of three dosing regimenes of docetaxel polymer micelle for injection in patients with advanced esophageal cancer, and to determine the best dosing regimenes for entering the expansion stage. The expansion stage iwas used to evaluate the efficacy and further safety of the best dosing regimen identified in the dose confirmation stage in patients with advanced solid tumors. All subjects in the dose confirmation stage and expansion stage will continue treatment according to the injection docetaxel micelle regimen they received at enrollment until the disease progresses or the investigator determines that continuing treatment with the study drug will not benefit, or any intolerable toxicity occurs, or they voluntarily withdraw, or for other reasons, whichever occurs first.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Male or Female aged 18~75 years old

• Patients with histopathologically or cytologically confirmed advanced or metastatic solid tumors who have failed or are not eligible for standard therapy in the past

• Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• There are measurable tumors(RECIST 1.1)

Exclusion Criteria:

• Previous palliative chemotherapy with docetaxel failed

• Central nervous system metastasis or meningeal metastasis with clinical symptoms

• Has a history of serious cardiovascular disease

• A history of immunodeficiency, including a positive test for human immunodeficiency virus (HIV)

• Active hepatitis B (HBsAg positive, HBV DNA>; ULN) or hepatitis C (HCV antibody positive and HCV RNA>ULN)

• Has a history of allergies to yew medications

• Pregnant or lactating women

• The investigator considered that there were other reasons for the subjects' ineligibility for this clinical study